DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Amirfallah, ArsalanKocal, Gizem Calibasi
Unal, Olcun Umit
Ellidokuz, Hulya
Oztop, Ilhan
Basbinar, Yasemin
Issue Date
2018-12-13
Metadata
Show full item recordCitation
DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients. 2018, 8(4). pii: E45 J Pers MedAbstract
Fluoropyrimidine-based chemotherapy is extensively used for the treatment of solid cancers, including colorectal cancer. However, fluoropyrimidine-driven toxicities are a major problem in the management of the disease. The grade and type of the toxicities depend on demographic factors, but substantial inter-individual variation in fluoropyrimidine-related toxicity is partly explained by genetic factors. The aim of this study was to investigate the effect ofDescription
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked DownloadAdditional Links
https://www.mdpi.com/2075-4426/8/4/45ae974a485f413a2113503eed53cd6c53
10.3390/jpm8040045
Scopus Count
Collections
Related articles
- The Role of <i>Dihydropyrimidine Dehydrogenase</i> and <i>Thymidylate Synthase</i> Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population.
- Authors: Abbasian MH, Ansarinejad N, Abbasi B, Iravani M, Ramim T, Hamedi F, Ardekani AM
- Issue date: 2020 Jul-Sep
- Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
- Authors: Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM
- Issue date: 2013 Jun 25
- Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
- Authors: Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G
- Issue date: 2004 Dec
- Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
- Authors: Cho HJ, Park YS, Kang WK, Kim JW, Lee SY
- Issue date: 2007 Apr
- Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
- Authors: Sharma R, Hoskins JM, Rivory LP, Zucknick M, London R, Liddle C, Clarke SJ
- Issue date: 2008 Feb 1